







Marshall, G.E., Russell, J.A. , Tellez, J.O., Jhund, P.S. , Currie, S., 
Dempster, J., Boyett, M.R., Kane, K.A., Rankin, A.C. , andWorkman, 
A.J. (2011) Remodelling of human atrial K+ currents but not ion channel 
expression by chronic β-blockade.Pflügers Archiv - European Journal of 




Deposited on: 15 December 2011 
 
 




Remodelling of human atrial K+ currents 
but not ion channel expression by chronic β-blockade 
 
 
Marshall GE1, Russell JA1, Tellez JO 2, Jhund PS1, Currie S3, Dempster J3, Boyett MR2, Kane KA3, Rankin 
AC1, Workman AJ*1 
 
1BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK, 2School of Medicine, 





Dr Antony J Workman, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary 
and Life Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, United Kingdom. 
Tel.: +44 (0)141 330 3451. Fax.: +44(0)141 330 6997. Email: Antony.Workman@glasgow.ac.uk  
 
Word count (excluding references): 5769 
 
 
Abstract (250 words) 
Background: Chronic β-adrenoceptor antagonist (β-blocker) treatment in patients is associated with a 
potentially anti-arrhythmic prolongation of the atrial action potential duration (APD), which may involve 
remodelling of repolarising K+ currents. Objective: To investigate the effects of chronic β-blockade on 
transient outward, sustained and inward rectifier K+ currents (ITO, IKSUS and IK1) in human atrial myocytes and 
on the expression of underlying ion channel subunits. Methods: Ion currents were recorded from human right 
atrial isolated myocytes using the whole-cell-patch clamp technique. Tissue mRNA and protein levels were 
measured using real time RT-PCR and western blotting. Results: Chronic β-blockade was associated with a 
41% reduction in ITO density: 9.3±0.8 (30 myocytes, 15 patients) vs 15.7±1.1 pA/pF (32, 14), p<0.05; 
without affecting its voltage-, time- or rate-dependence. IK1 was reduced by 34% at -120 mV (p<0.05). 
Neither IKSUS, nor its increase by acute β-stimulation with isoprenaline, were affected by chronic β-blockade. 
Mathematical modelling suggested that the combination of ITO- and IK1-decrease could result in a 28% 
increase in APD90. Chronic β-blockade did not alter mRNA or protein expression of the ITO pore-forming 
subunit, Kv4.3, or mRNA expression of the accessory subunits KChIP2, KChAP, Kvβ1, Kvβ2 or frequenin. 
There was no reduction in mRNA expression of Kir2.1 or TWIK to account for the reduction in IK1. 
Conclusion: A reduction in atrial ITO and IK1 associated with chronic β-blocker treatment in patients may 
contribute to the associated action potential prolongation, and this cannot be explained by a reduction in 
expression of associated ion channel subunits.  
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 Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and is associated with 
significant morbidity and mortality [3]. Beta-adrenoceptor antagonists (β-blockers) are used in the treatment 
of AF to control the ventricular rate, and they also exert atrial anti-arrhythmic effects [22]. The mechanisms 
underlying these atrial anti-arrhythmic effects are multifactorial [32, 36], but there is evidence to suggest that 
long-term treatment with β-blockers can alter atrial cellular electrophysiology by prolonging the action 
potential duration (APD) and effective refractory period (ERP) [29, 35] and, therefore, potentially inhibiting 
intra-atrial reentry. 
 This “pharmacological remodelling” [35] of atrial action potentials in patients treated chronically with β-
blockers was initially demonstrated by our group to be associated with a reduction in the density of the atrial 
transient outward K+ current, ITO. However, the electrophysiological and molecular mechanisms of this ion 
current change are unknown. Thus, the effects of chronic β-blockade on characteristics of human atrial ITO 
other than its amplitude, such as voltage-dependency and kinetics, have not yet been investigated. 
Furthermore, the effects of chronic β-blockade on the expression of ion channel proteins which carry and 
modulate this current; proteins known to be associated with electrophysiological remodelling in AF and 
other cardiac pathologies [24], also have not yet been studied. 
 Preliminary data from our laboratory have suggested that chronic β-blockade may also reduce the human 
atrial inward rectifier K+ current, IK1, since the atrial cellular input resistance was reduced in patients taking 
β-blockers [35], although this current was not measured directly. Since there is increasing evidence to 
suggest that an increase in IKI may be a crucial determinant of the pro-arrhythmic atrial APD-shortening seen 
in AF-remodelling [28], it is important to establish the effects of chronic β-blockade on IK1 and on the 
expression of ion channel proteins associated with this current.  
 The aims of this study, therefore, were to investigate the effects of chronic β-blockade in patients on the 
time- and voltage-dependent characteristics of the main repolarising K+ currents in human atrium and on the 
expression of their underlying ion channel subunits, and also to investigate the likely effects of these ion 





Human atrial myocyte isolation 
Right atrial appendage tissues were obtained from adult patients undergoing cardiac surgery, who were in 
sinus rhythm with no history of AF, and either treated with a β-blocker for a minimum of 4 weeks prior to 
surgery, or not treated with a β-blocker. All procedures were approved by the institutional ethics committee 
(99MC002) and informed consent was obtained from all patients. The investigation conforms with the 
principles outlined in the Declaration of Helsinki. Atrial myocytes were isolated by enzymatic dissociation 
and mechanical disaggregation, as described in detail previously [33]. Briefly, tissue chunks were shaken for 
45 min in a low [Ca2+] (50 µM) solution containing protease (4 U/ml Type XXIV, Sigma). Protease was then 
replaced by collagenase (400 U/ml Type 1, Worthington), which was exchanged 3 times, at 15 min intervals. 
At each exchange, cells were separated by filtration through nylon gauze and centrifugation at 40 g for 2 
min, and washed of residual enzyme in a high [K+], low [Ca2+] solution. Cells were stored in a 0.2 mM Ca2+-
containing physiological salt solution for up to 8 hr before electrical recording. 
 
Electrical recording 
Ion currents were recorded from human atrial myocytes using the whole-cell-patch clamp technique with an 
Axopatch-1D amplifier (Axon Instruments) in voltage-clamp mode in conjunction with WinWCP software (J 
Dempster, Strathclyde University). Myocytes were superfused at 37 ºC with a solution containing (mM): 
NaCl (130), KCl (4.0), MgCl2 (1), CaCl2 (2), CdCl2 (0.2), glucose (10) and HEPES (10); pH 7.35. The 
pipette solution contained (mM): K-aspartate (110.0), KCl (20.0), MgCl2 (1.0), EGTA (0.15), Na2ATP (4.0), 
Na2GTP (0.4) and HEPES (5.0); pH 7.25. A liquid junction potential of -7 mV was compensated for prior to 
recordings, as were capacitative transients and series resistances (64-72% compensation). Voltage-dependent 
activation of ITO was measured by stimulating cells at 0.3 Hz from a holding potential of -50 mV, with 
voltage pulses of 100 ms duration increasing in 10 mV steps from -40 to +60 mV. ITO amplitude was 
calculated as the peak outward current minus end-pulse current. IKSUS, considered to reflect mainly the ultra-
rapid delayed rectifier K+ current, IKur [25], was measured as the end-pulse current. Voltage-dependent 
inactivation of ITO was measured using a 1 s pre-pulse which was increased from -90 mV to +60 mV in 10 
mV steps, followed by a second, 100 ms pulse, to +60 mV. ITO reactivation was measured using a standard 
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S1-S2 pulse protocol with an initial inter-pulse interval of 500 ms, which was reduced in 50 ms intervals to 
150 ms, and then by 10 ms intervals to 10 ms. ITO rate-dependence was measured using 6 trains of 8 pulses at 
75-500 beats/minute. Barium (0.5 mM)-sensitive IK1 voltage-dependent activation was determined using 500 
ms voltage pulses increasing from -120 mV to +60 mV in 10 mV steps. In a subset of cells, the effect of 
acute β-adrenoceptor stimulation with isoprenaline (ISO) on IK1 (in the absence of Ba2+), ITO and/or IKSUS, 
was assessed. ISO was used at 1 µM; close to Emax concentration for human atrial IKur [20]. 
 
Mathematical modelling 
To investigate the potential contribution of changes in ion currents to the action potential (AP) configuration, 
such changes were simulated using a well established mathematical model of the human atrial AP; described 
in Courtemanche et al [6] and implemented using the CESE Pro 1.4.8 modelling software (Simulogic Inc., 
Halifax, Canada). Since the typical AP configuration recorded in human atrial cells from our laboratory [35] 
is Type 3 (or “no dome” [8]), and the Courtemanche model typically produces Type 1 APs (or “spike and 
dome”) [8], we modified the model to produce “no dome” APs that mimicked those recorded in our 
laboratory, as follows. The L-type Ca2+ current (ICaL) and IKSUS are the largest two currents that contribute to 
the plateau (“dome”) phase of the action potential in the Courtemanche model: see Figure 2 of [32] and 
Figure 14 of [6]. The peak conductance of ICaL in the Courtemanche model (0.124 nS/pF) is larger than that 
typically recorded in our laboratory (0.099 nS/pF; [35]), and the peak conductance of IKur in the 
Courtemanche model (0.054 nS/pF) is smaller than that recorded in cells in the present study (0.075 nS/pF). 
Therefore, ICaL and IKur conductances were decreased and increased, respectively, in steps of 10%, until the 
resulting action potential closely resembled that from a representative cell obtained from a patient not treated 
with a β-blocker: Figure 1A of [35]. This was achieved with a 50% scaling of ICaL and 150% IKur, i.e., peak 
conductances of 0.062 nS/pF and 0.081 nS/pF, respectively.  
 
Quantitative real-time PCR 
Human atrial tissue samples were stored at -20oC in RNAlater solution (Quiagen), before cryosectioning at 
20 µm. Total RNA was extracted using RNeasy Mini Kit (Quiagen) and reverse transcribed with Superscript 
III reverse transcriptase (Invitrogen), using random hexamer priming and a PCR thermo-cycler 
(Thermohybaid PCR Express). The relative abundance of cDNA was determined using an ABI 7900HT Fast 
Real-Time PCR system (Applied Biosystems), Power SYBR Green PCR MasterMix (Applied Biosystems) 
and primer assays (10x QuantiTect, Quiagen or Applied Biosystems) (Table 1). Samples were tested in 
triplicate for each primer with a 40-cycle PCR reaction followed by melting curves. Negative controls 
consisted of molecular grade water. Mean threshold cycles (Ct) values were determined and ∆Ct derived 
relative to one tissue sample used as an internal calibrator for each primer reaction. cDNA abundance for 
each tissue sample (a) was expressed relative to mean abundance of 28S and GAPDH (b) for that sample, 
using the equation: relative abundance=Ea∆Cta/Eb∆Ctb. E=efficiency of the PCR reaction and was determined 
from √Fn/F-2n, where F=fluorescence at the end of each elongation step and n=cycle number.  
 
Western blotting 
Human atrial tissue samples were homogenised for 90 s with an Ultraturrax T8 homogeniser (VWR) in 1 ml 
of homogenisation buffer containing: 15 µl protease inhibitor (Sigma P8340), NaCl 150 mM, KCl 5.4 mM, 
MgCl2 1.2 mM, NaHEPES 5 mM, Glucose 10 mM, CaCl2 1.0 mM; pH 7.4, and stored at -80°C. Kv4.3 and 
GAPDH protein levels were measured using sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE), immunoblotting and optical densitometry. Tissue samples were blinded with respect to β-
blocker status and randomised so that 2 samples from β-blocked and 2 from non-β-blocked patients were 
loaded onto each gel, at concentrations which we first established to result in a linear relationship with 
optical density (total protein load of 5-10 µg per lane). Electrophoresis and immunoblotting were performed 
using the NuPAGE system (Invitrogen) with 4-12% gradient Bis-Tris NuPAGE gels, and molecular weight 
marker Magic Mark Western Standard. Protein immunodetection was performed using the Invitrogen 
Western Breeze kit unless otherwise stated, and analysed using Quantity-One software (BIORAD). Blots 
were incubated overnight with monoclonal anti-Kv4.3 (Neuromab) at 1:133 or anti-GAPDH (mAbcam 9484) 
at 1:20000. Western blotting controls were performed using rabbit and rat brain or lung tissues. All 
procedures conformed with the Institutional Guidelines for the Care and Use of Animals, and with the 
Guidance on the Operation of the Animals (Scientific Procedures) Act 1986. A New Zealand White rabbit 
was killed with an intravenous injection of 100 mg/kg pentobarbital sodium (UK Project Licence No. 
PPL60/3538), and a Wistar rat was killed by cervical dislocation in accordance with Schedule 1. Tissue 
homogenates were used to compare bands generated by the monoclonal primary antibody (Neuromab anti-
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Kv4.3) plus secondary antibodies with secondary antibody alone, and also to compare a polyclonal anti-
Kv4.3 (Alomone) at 1:1600 with a solution of this antibody pre-incubated with Kv4.3 antigenic peptide 
(Alomone) at 1:10.  
 
Statistical analysis 
Comparisons between patient groups for current and ion channel expression were made using Student’s t-tests, 
with Graphpad Prism software. Multiple linear regression was performed using Stata Version 10, Stata Corp., 






Table 2 shows the patients’ clinical characteristics, and a comparison between treatment and non-treatment 
with a β-blocker. The majority of patients underwent coronary artery bypass graft surgery (89%) and had 
angina (88%). LV function was normal in 74% of patients. Of the patients treated with a β-blocker, 95% 
received a cardiac selective β1-adrenoceptor antagonist (atenolol or bisoprolol), and 2 patients received 
carvedilol, which additionally antagonises β2- and α1-receptors. No patient was given sotalol (which has 
additional class III activity). Patients treated and not treated with a β-blocker were generally of similar age, 
male-female ratio and disease history (Table 2). Those receiving a β-blocker had a lower incidence of calcium 
channel blocker use, and a lower heart rate (Table 2). 
 
Chronic β-blockade reduced the density of human atrial ITO and IK1, but not IKSUS 
Figure 1A shows representative current traces of ITO and IKSUS voltage-dependent activation in myocytes of 
similar capacitance from a non-β-blocked patient and a β-blocked patient. There was a significant reduction 
in mean ITO density at all voltages from +10 to +60 mV associated with chronic β-blockade (Figure 1B). 
Peak ITO density at +60 mV was 41% lower in myocytes from patients treated with a β-blocker compared to 
non-β-blocked patients (Figure 1C). There was no significant difference in mean capacity of these cells 
between patients treated and not treated with a β-blocker (67±4 vs 76±3 pF; p>0.05). Single linear regression 
analysis of the effects of chronic β-blockade on ITO demonstrated a change in current density of -4.14 pA/pF 
(95% CI -7.50 to -0.77, p<0.05). There was a significant reduction in ITO density of -4.19 pA/pF (95% CI -
7.88 to -0.49, p<0.05) in association with chronic β-blockade after adjusting for calcium channel blocker use. 
In a separate model, adjusting for heart rate, chronic β-blockade was not statistically significantly associated 
with ITO density, -1.61 pA/pF (95% CI -6.35 to 3.14, p=0.49). There was no difference in peak IKSUS density, 
recorded in the same cells, between β-blocked and non-β-blocked patients (Figure 1C). Figure 2 shows mean 
current-voltage relationships for Ba2+-sensitive IK1, recorded in 21 cells from β-blocked patients and 31 cells 
from non-β-blocked patients; several of which (6 and 9 cells, respectively) were used to record ITO. There 
was a significant, 34% reduction in peak IK1, at -120 mV, in myocytes from β-blocked patients, and no 
significant difference in IK1 at the less negative potentials at which the small outward portion of the current 
occurred. There was no significant difference in mean capacity of cells in which IK1 was recorded, between 
β-blocked and non-β-blocked patients (85±5 vs 87±4 pF; p>0.05).  
 
Chronic β-blockade did not affect voltage-, time- or rate-dependent properties of human atrial ITO 
The voltage-dependences of ITO activation and inactivation were not significantly different between 
myocytes from β-blocked and non-β-blocked patients (Figure 3A). The voltage of half maximal activation 
(V0.5) in β-blocked patients was 25.1±0.7 mV (29 myocytes, 15 patients) vs 23.8±0.5 mV (32 myocytes, 14 
patients) in the non-β-blocked group (p>0.05). Inactivation V0.5 in cells from β-blocked and non-β-blocked 
patients was -19.0±1.0 mV (29, 13) vs -19.5±0.6 mV (32, 15), p>0.05. ITO time-dependent inactivation was 
bi-exponential in 93% of β-blocked patients and in 100% of non-β-blocked patients, and the resulting curve 
fits are shown in Figure 3B. The mean fast rate constants (inverse of time constants) were 0.16±0.01 for β-
blocked patients (22 myocytes, 13 patients) and 0.15±0.01 for non-β-blocked patients (27 myocytes, 15 
patients), p>0.05. The corresponding slow rate constants were 0.03±0.01 and 0.04±0.01, p>0.05, 
respectively. The contribution of each exponential to ITO inactivation in these cells, i.e., the amplitude of the 
fast and slow inactivation phases, was also not significantly different (p>0.05 for each phase) between the 
two patient groups (Figure 3B inset). ITO reactivation is shown in Figure 3C. Mean S2 ITO current densities 
were normalised to the 1st post-rest pulse of the protocol. Initially, at long inter-pulse intervals, ITO density 
remained unchanged, in keeping with the rapid recovery of ITO from inactivation [11]. As the inter-pulse 
 5/18
interval was shortened to <150 ms, ITO reduced in myocytes from both patient groups. ITO reactivation in 
80% of myocytes from β-blocked patients (24 myocytes, 12 patients) and in 93% from non-β-blocked 
patients (28 myocytes, 13 patients) best fitted a mono-exponential curve (Figure 3C). The time-course of ITO 
reactivation for each patient group was virtually superimposable, with mean time constants of reactivation of 
33.5±2.6 ms and 31.3±1.9 ms, respectively; p>0.05. ITO density reduced significantly with increasing 
stimulation rate; reversible and not different between myocytes from β-blocked and non-β-blocked patients 
(Figure 3D). The reduction in ITO density associated with chronic β-blockade was maintained even at rapid 
rates. 
 
Acute β-adrenergic stimulation increased atrial IKSUS; an effect not modified by β-blocker therapy 
In atrial cells from a group of patients not treated with a β-blocker, acute superfusion with ISO (1 µM) 
significantly increased IKSUS, and had no significant effect on IK1 or ITO (Figure 4A). A similar increase in 
IKSUS and lack of change in IK1 or ITO was found in response to ISO in cells from a group of patients who 
were treated chronically with a β-blocker (Figure 4B).  
 
Mathematical modelling of human atrial ion current changes associated with chronic β-blockade 
Action potentials (AP) from the Courtemanche model featured a prominent plateau (phase 2) and a marked 
“spike and dome” (Type-1) morphology (trace i in Figure 5A). We progressively reduced the plateau 
amplitude by sequentially scaling ICaL and IKsus, until the AP configuration and approximate APD at 90% 
repolarisation (APD90) as recorded previously in our laboratory in atrial myocytes from non-β-blocked 
patients [35], was attained: trace ii in Figure 5A (APD90=186 ms). Repeating this simulated AP (trace ii) with 
IK1 reduced by the same magnitude as observed at -120 mV in the myocytes from β-blocked patients, 34% 
(Figure 2), resulted in a 26% increase in APD90 (Figure 5B). A simulated voltage-ramp-clamp of IK1 
indicated that this AP change was due to a reduction in outward IK1 (Figure 5C). Reducing ITO independently 
by 41%, i.e. as associated with β-blocker therapy (Figure 1C), also prolonged APD90 (Figure 5E), but by a 
lesser degree, 9%, than with IK1 reduction. Simultaneous reduction in IK1 and ITO resulted in a 28% increase 
in APD90 (Figure 5F), versus a 21% increase previously associated with β-blocker therapy [35]. By contrast, 
using the Type-1 AP (non-representative of APs recorded from our laboratory; trace i of Figure 5A), the 
same reductions in IK1, ITO, and their combination, produced negligible changes in APD90: 3% increase; 2% 
decrease; and 2% increase, respectively. 
 
Chronic β-blockade did not reduce mRNA expression of human atrial K+ channel subunits 
Figure 6A-F shows the relative mean abundance of mRNA for Kv4.3, the pore-forming ion channel α-
subunit responsible for ITO, and its accessory protein subunits KChIP2, Kvβ1, Kvβ2, KChAP and frequenin 
[27]. The expression of mRNA for these subunits was not different in the tissue samples from β-blocked 
patients compared to those from non-β-blocked patients. There was also no change in the expression of 
Kv1.5, the pore-forming ion channel α-subunit carrying IKSUS [26] (Figure 6G). Kir2.1, one of the pore-
forming subunits carrying IK1 tended to increase in the tissue from β-blocked patients (p=0.05; Figure 6H), in 
contrast to the reduction in current density in this patient group. Kir2.2 was not detectable in either group of 
tissue samples, and there was no change in TWIK-1, the pore-forming subunit of a weak inwardly-rectifying 
current that may contribute to IK1 [26, 19] (Figure 6I). Expression of pore-forming subunits for ICaL and the 
Na+/Ca2+-exchanger (Cav1.2 and NCX-1, respectively) also did not differ between patient groups. 
 
Chronic β-blockade did not affect Kv4.3 protein expression in human atrial tissue 
Kv4.3 was detected in western blots using two primary antibodies: a monoclonal antibody, and a polyclonal 
antibody which was supplied with the corresponding antigen for use in control experiments. The polyclonal 
anti-Kv4.3 detected Kv4.3 at 65 kDa in rat and rabbit brain tissue, in which Kv4.3 is highly expressed, and 
this band was markedly reduced when the antibody was pre-incubated with the Kv4.3 antigen (Figure 7A). 
This polyclonal primary antibody did not detect any similar band in human atrial tissues, presumably 
because of lower levels of Kv4.3 expression, and hence the monoclonal antibody was then used for increased 
sensitivity. This monoclonal anti-Kv4.3 also detected Kv4.3 at 65 kDa in the rodent brain tissue positive 
control, and this band was markedly reduced in rodent lung tissue, in which Kv4.3 expression is minimal 
[17] (Figure 7B). Using this antibody, a band at 65 kDa was also detected in human atrial tissue (Figure 7B). 
The specificity of this antibody was tested by excluding non-specific secondary antibody binding (Figure 
7B). No antigenic peptide was available for control testing with this monoclonal antibody. Figure 7C shows 
a western blot of continuously varying concentrations of total protein from tissue from two β-blocked and 
two non-β-blocked patients. The blot was cut horizontally just above the 40 kDa marker (dashed horizontal 
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line in Figure 7C) prior to incubation with primary antibody. The top half was treated with the monoclonal 
anti-Kv4.3 and the bottom with a monoclonal anti-GAPDH that detected GAPDH at 38 kDa. There was no 
significant difference in the mean optical density (OD) of either GAPDH (9.56±0.70 vs 10.66±1.61 
ODu/mm2, p>0.05) or Kv4.3 (11.44±1.03 vs 11.57±1.31 ODu/mm2, p>0.05) between tissues from β-blocked 
(n=8) and non-β-blocked (n=10) patients. All ODs were compared at total protein load 7.5 µg. The ratios of 
Kv4.3:GAPDH were 1.24±0.13 in samples from β-blocked, and 1.30±0.27 in samples from non-β-blocked, 




 This is the first study, to our knowledge, to show that the chronic treatment of patients in sinus rhythm 
with β-blockers is associated with a significant reduction in both atrial ITO and IK1; that the reduction in ITO 
occurred without any changes in its time-, rate- or voltage-dependence; and that neither ion current change 
resulted from any changes in expression of underlying ion channel subunits. Furthermore, we suggested, 
using mathematical modelling, that the combination of the reduction in ITO and IK1 may contribute to the 
established prolongation of atrial action potential repolarisation in patients treated with β-blockers. 
 The magnitude of ITO reduction was similar to that found in a previously reported smaller study by our 
group [35], in which other properties of this current were not measured. Further supporting these findings, 
chronic treatment of rabbits with the β-blocker carvedilol reduced atrial ITO [4], but no other studies 
examining the effects on human atrial ITO could be found. However, in catecholamine-depleted rats, and also 
in rats with chronically reduced cardiac sympathetic innervation, ventricular ITO was reduced in conjunction 
with prolongation of the APD [2, 21]. Given the rapid inactivation kinetics of ITO, the effect of changes in 
this current on late repolarisation is presently unclear and under debate [7, 14, 10]. We established that 
chronic β-blockade in patients was also associated with a reduction in atrial IK1, measured as the inwardly-
rectifying Ba2+-sensitive current, and this might be expected to prolong action potential terminal 
repolarisation [12]. Our mathematical modelling of changes in ITO and IK1 suggested that the reduction in 
each current alone could result in APD-prolongation, and also that when combined, these ion current changes 
could prolong the APD as much as was reported with chronic β-blockade [35]. Of the two currents, IK1 might 
be expected to contribute more to the APD-prolongation. Upregulation of IK1 in chronic AF is considered to 
be a crucial factor in stabilising the high frequency rotors that help to sustain fibrillation [28], and it is 
conceivable that the present reduction of IK1 seen in patients treated with β-blockers might contribute to their 
anti-arrhythmic actions by opposing such rotor stabilisation. 
 We found that pharmacological remodelling by chronic β-blockade was not associated with any change 
in the expression of the ITO ion channel pore, Kv4.3, either at protein or mRNA level. There was also no 
change in the expression of mRNA for its related ion channel subunits, although the protein expression of 
these subunits was not measured. While some accessory subunits, such as KChAP and KChIP2 are involved 
in trafficking of Kv4.3 to the cell membrane and, therefore, directly influence current density, many subunits 
modify multiple current characteristics of ITO additional to its density [27]. Therefore, the observed absence 
of change in the expression of ITO accessory subunits is consistent with the observed absence of change in ITO 
voltage- and time-dependent characteristics. The reduction in IK1 density was not the result of any significant 
reduction in mRNA expression of potential pore-forming components, Kir2.1 or TWIK, although neither 
was examined at protein level as part of this study. 
 We show here ion current changes, by pharmacological remodelling, that did not require changes in the 
expression of associated ion channel pore-forming or accessory subunits. This appears to contrast with some 
of the ion current changes which occur in chronic AF [34] that have been associated with changes in 
expression of corresponding ion channels [9]. However, there are exceptions, e.g., with dramatic changes in 
ICaL in chronic AF without corresponding changes in protein expression [5, 13, 31, 15]. Perhaps the most 
likely explanation underlying ion current reduction in the present study is a chronic β-blockade-induced, 
post-translation alteration in ion channel structure or function. This could result in changes to trafficking of 
ion channel components to the cell membrane, or to their turnover or recycling from the cell membrane, or to 
their interaction with other channel subunits and signalling molecules. The potential of chronic β-blockade to 
alter phosphorylation-dependent changes in channel function is one possible post-translation modification. 
Adrenoceptor-signalling is complex and varies with chronicity of stimulation. However, cyclic AMP-
dependent protein kinase A (PKA), PKC and Ca2+-calmodulin-dependent protein kinase II (CaMKII) are all 
implicated in multiple downstream signalling pathways [37]. In addition, β-adrenoceptors localise to cardiac 
cell membrane lipid microdomains or caveolae, where they may interact or recruit ion channel subunits [23]. 
CaMKII has been shown to associate with Kv4.3 and can alter channel function and trafficking to the cell 
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membrane by phosphorylation, as well as affecting gene transcription [27]. Kv4.3 has potential sites for 
phosphorylation by PKA and PKC, both of which can affect channel function [27]. PKA-dependent 
phosphorylation has been implicated in localisation of ITO channel complexes in the cell membrane to lipid 
microdomains via interaction with caveolin-3 [1]. In addition, human cardiac IK1 is also inhibited by both 
PKC and PKA-dependent signalling pathways [18, 16]. In the present study, acute β-stimulation increased 
IKSUS and had no effect on ITO or IK1, consistent with previous reports in human atrium (recently reviewed 
[32]). Furthermore, β-blocker therapy did not alter the ISO-response of these currents, consistent with a 
reported lack of effect of β-blocker therapy on ICaL increase by ISO [30]. However, remodelling by β-blocker 
therapy of other ion current or biochemical responses to β-, or α-, stimulation, should not be excluded. 
 Study limitations: We studied cells from patients in sinus rhythm, and it is unknown whether the ability 
of β-blocker therapy to alter ion currents and action potentials is preserved in cells from patients with chronic 
AF. It should be noted, however, that β-blockers are used in the treatment of a variety of cardiac pathologies 
that predispose to AF, including ischaemia, heart failure and hypertension, all of which may cause 
potentially pro-arrhythmic electrophysiological remodelling [24, 36]. The effects of the potentially anti-
arrhythmic remodelling of ITO, IK1 and APD by chronic β-blockade may, therefore, be expected to participate 
in addition to anti-adrenergic, anti-ischaemic, and structural remodelling effects of β-blockers. We focussed 
on ITO, IKSUS and IK1. ICaL is unaffected by β-blocker therapy [32], but other currents remain to be studied, 
e.g., IKACh, IKr, IKs and INa/Ca, as well as intracellular Ca2+ homeostasis. In the mathematical modelling study, 
we reduced IK1 by 34%, as was observed at -120 mV, although no change in IK1 was detected at more 
positive potentials. Inward IK1 is large and easily quantifiable at -120 mV, but it is recognised that outward 
IK1 at more positive potentials is small, and that the “small expression levels of IK1 indicate that the ‘natural 
variability’ between cells may make it difficult to determine how much IK1 is present at plateau potentials” 
[12]. Any effect of chronic β-blockade to reduce IK1 at such potentials may, therefore, be difficult to discern 
under voltage-clamp conditions. Since cardiac myocytes have a high resistance at the end of the plateau, the 
APD at this phase is very sensitive to intrinsic net current changes. We therefore considered it important to 
model a reduction in outward IK1 to investigate potential ionic mechanisms of effects of β-blockade on APD, 
and reasonable to assume a reduction of 34%. However, we do not exclude the possibility that β-blockade 
decreases IK1 at negative potentials without affecting outward IK1, through some modification of the voltage-
sensitivity of IK1 channel gating, and that ion current changes additional to the observed reduction in ITO and 
IK1 are responsible for the increase in APD. 
 In conclusion, this study improves our understanding of electrophysiological and molecular mechanisms 
of the potentially anti-arrhythmic prolongation of human atrial action potentials associated with the chronic 
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Table 2. Patient characteristics. Values are numbers of patients [n; (% of total within group)] with specified 
clinical characteristics, except for age and heart rate (mean±SEM), in groups of patients not treated, or 
treated chronically, with a beta-adrenoceptor antagonist (β-blocker: no, and β-blocker: yes, respectively). 
Age and heart rate were compared between groups by unpaired Student’s t-test; categorical data by χ2 with 
Yates’ correction. *=p<0.05. CABG=coronary artery bypass graft, AVR=aortic valve replacement, 
MVR=mitral valve replacement, CCB=calcium channel blocker, LVSD=left ventricular systolic dysfunction, 











Total patients 35 38 - 
Male/female 28/7 26/12 0.390 
Age (years) 63.7±1.7 64.9±1.4 0.606 
Heart rate (beats.min-1)  74±2 57±2 <0.0001* 
CABG 30 (86) 35 (92) 0.618 
AVR 7 (20) 3 (8) 0.245 

















ACE inhibitor 15 (43) 21 (55) 0.409 
CCB 19 (54) 8 (21) 0.007* 
Statin 31 (89) 38 (100) 0.103 
Nicorandil 19 (54) 15 (39) 0.302 
Digoxin 1 (3) 0 (0) 0.967 
No LVSD 24 (69) 30 (79) 0.458 
Mild/moderate LVSD 11 (31) 7 (18) 0.310 
Severe LVSD 0 (0) 1 (3) 0.967 
Previous MI 12 (34) 13 (34) 0.810 
Angina 30 (86) 34 (89) 0.895 
Hypertension 17 (49) 24 (63) 0.308 
























Figure 1. Chronic β-blockade is associated with a reduction in the density of human atrial ITO, but not IKSUS. 
(A) Representative current traces of ITO and IKSUS in isolated atrial myocytes from a patient treated ( ) or not 
treated ( ) with a β-blocker. (B) Mean±SEM current-voltage-relationship for ITO density ( : n=30 myocytes, 
15 patients, : n=32 myocytes, 14 patients) (C) Mean±SEM peak ITO and IKSUS densities at +60 mV. 
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Figure 2. Chronic β-blockade is associated with a reduction in the inward component of IK1 (at -120 mV). 
Values are means±SEM current-voltage-relationship for Ba2+-sensitive IK1, in myocytes from patients treated 
( : n=21 myocytes, 11 patients) or not treated ( : n=31 myocytes, 12 patients) with a β-blocker. *=p<0.05. 
 



















Figure 3. Lack of effect of chronic β-blockade on voltage- or time-dependent characteristics of ITO. Open 
symbols are data (means±SEM) from non-β-blocked patients (n=27-32 cells, 11-15 patients); filled symbols 
from β-blocked patients (17-29 cells, 6-15 patients). (A) Boltzmann curves-fits for voltage-dependent 
activation ( ) and inactivation (---). (B) Bi-exponential curve-fits showing time-dependent ITO inactivation 
at +60 mV. Inset shows amplitudes of fast and slow inactivation phases, respectively. (C) Mono-exponential 
curve-fits showing ITO reactivation. Inset is an enlarged version of main graph at short interpulse intervals of 
the 2-pulse activation protocol. (D) ITO rate-dependence: normalised steady-state (8th pulse) ITO density vs 
stimulation rate.  
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Figure 4. Effects of acute β-adrenoceptor stimulation on K+ currents in human atrial cells, and lack of effect 
of chronic β-blocker therapy. (A) Patients not treated with a β-blocker (n=14-15 cells, 3 patients). (B) 
Patients treated with a β-blocker (n=11-14 cells, 3-4 patients). CON=control; ISO=superfusion with 
isoprenaline 1 µM for 90 s. IK1 was measured as inward current at -120 mV. ITO and IKSUS were measured at 





































































































Figure 5. Mathematical modelling of ion current changes associated with β-blocker therapy. (A) 
Superimposed simulated APs (last APs of 1 Hz trains of 8 APs) resulting from progressive (in 10% steps) 
simultaneous ICaL-decrease and IKsus-increase. Trace i=100% ICaL+100% IKsus; ii=50% ICaL+150% IKsus; iii=0% 
ICaL+200% IKsus. (B) Effect of reducing IK1 on AP shape. Control AP=trace ii of panel A. (C) Effect of 
reducing IK1 on simulated quasi-steady-state IK1-voltage relationship obtained with the voltage-ramp in D. 
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Figure 6. Mean±SEM abundance of mRNA relative to 28S and GAPDH for ion channel subunits associated 
with the ion currents ITO, IKSUS and IK1, in atrial tissues from β-blocked ( ; n=8) and non-β-blocked 







































































































































































































A  Kv4.3 B  KChIP2 C  Kvβ1 
D  Kvβ2 E  KChAP F  Frequenin 









































Figure 7. Western blots of Kv4.3. Molecular weight markers are indicated in kDa. (A) Kv4.3 was detected 
at 65 kDa in rat brain (rB) and rabbit brain (RB) using polyclonal α-Kv4.3 primary antibody (1ºAb) (left 
section of membrane), and was markedly reduced when treated with 1ºAb pre-incubated with antigen, Ag 
(right). (B) Kv4.3 was also detected at the same molecular weight using a monoclonal 1ºAb in both rodent 
brain and human atrium (HA), but was markedly reduced in negative control rabbit lung (RL), and absent 
with secondary antibody (2ºAb) only. (C) Increasing protein concentrations (5-10 µg) of whole human atrial 
homogenate from two β-blocked (BBYes) and two non-β-blocked (BBNo) patients treated with monoclonal 
α-Kv4.3 (upper section) or monoclonal α-GAPDH (lower section). 
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